Liraglutide: Uses, Benefits, Dosage and Safety
The daily GLP-1 that came before Ozempic. What liraglutide does, why it is still prescribed, and how it compares on weight and heart outcomes.
By Marguerite Vayle ·
Liraglutide is a daily injection sold as Victoza for type 2 diabetes and as Saxenda for weight management. It was the first GLP-1 medicine most people heard about, approved for diabetes in 2010 and for weight in 2014.
It works the same way semaglutide does, copying the gut hormone that signals fullness after a meal. The difference is that it clears from the body faster, so it needs injecting every day rather than once a week, and it produces roughly half the weight loss.
That sounds like a drug that has been superseded, and in most respects it has. It is still worth understanding for three reasons: it has the longest safety record in the family, it has a completed cardiovascular outcomes trial, and generics have changed its price considerably.
What is liraglutide?
Liraglutide is a synthetic analogue of human GLP-1, 97% identical to the natural hormone, given as a once-daily subcutaneous injection from a pre-filled pen.
Where it comes from
Natural GLP-1 is destroyed within about two minutes by the enzyme DPP-4. Liraglutide changes one amino acid and attaches a fatty acid chain that binds it to albumin in the blood, which stretches its half-life to around 13 hours.
Thirteen hours is enough for daily dosing and not enough for weekly. Semaglutide is the same idea taken further, with additional modifications that push the half-life to about a week. The two drugs are separated by chemistry rather than by concept.
Proposed mechanisms of action
- Appetite signalling. GLP-1 receptor activation in the hypothalamus and brainstem reduces hunger.
- Slowed gastric emptying. Food stays in the stomach longer, so fullness arrives sooner.
- Glucose-dependent insulin release. Insulin is released in response to a meal rather than continuously, which is why this class does not carry the hypoglycaemia risk older diabetes drugs do.
What liraglutide is claimed to do
Moderate weight loss
The claim is steady weight reduction of a size that is useful without being dramatic.
GLP-1 receptor agonism reduces appetite centrally and slows gastric emptying, the same mechanism as the weekly drugs at a shorter duration of action.
In practice that describes smaller meals without a constant sense of restriction, though the effect fluctuates more across the day than it does on a weekly drug, because blood levels rise and fall on a daily cycle rather than sitting flat.
This was measured in the SCALE trials, where adults on the weight management dose lost around 8% of body weight over a year. That is roughly half what semaglutide achieved in STEP.
Fewer cardiovascular events
The claim is that the drug reduces heart attacks, strokes and cardiovascular death in people with type 2 diabetes at high cardiovascular risk.
The mechanism is not fully settled and is thought to combine weight, blood pressure, glycaemic control and a direct effect on the vasculature.
What that looks like to a person is an event that does not happen.
This was measured in LEADER, a randomised placebo-controlled outcomes trial in over 9,000 people with type 2 diabetes, which reported a significant reduction in major adverse cardiovascular events. Liraglutide and semaglutide are the two drugs in this family with this class of evidence in hand.
Blood sugar control in type 2 diabetes
The claim is reliable HbA1c reduction, and this is the oldest use of the drug.
Glucose-dependent insulin secretion combined with reduced glucagon output lowers both post-meal and fasting levels.
Put another way, the pancreas responds when food arrives and the liver stops volunteering sugar when it has not.
This has been measured since 2010 and is supported by well over a decade of prescribing data as well as by the original trials, which is a longer real-world record than anything else in the family.
Weight management in adolescents
The claim is that it works in a population where most weight loss drugs have no licence at all.
The mechanism is unchanged; what differs is that the trial was run in people aged 12 and over.
For a family, the practical meaning is a licensed option rather than an off-label conversation.
This was measured in a randomised placebo-controlled trial in adolescents with obesity, and it is the reason liraglutide remains in use in a group where the weekly drugs have narrower approvals.
What the evidence actually supports
- Species and route. Human, at the route people use, across large randomised placebo-controlled trials.
- Concentration of sources. Novo Nordisk sponsored the pivotal work, now supplemented by more than a decade of independent prescribing and post-marketing data. That is a meaningfully stronger position than a drug resting on its sponsor's trials alone.
- Human data. SCALE for weight, LEADER for cardiovascular outcomes, and a long diabetes record. All published in full.
- What has not been looked at. Nothing substantial for a drug of this age. The honest limitation is not evidence but effect size: it does less than the weekly drugs.
Side effects and safety profile
Nausea, diarrhoea, constipation and vomiting are common early and after each dose increase, and mostly settle. Because dosing is daily, the pattern differs from the weekly drugs: the effect is steadier and the daily injection is itself the main practical complaint people report.
The label also excludes anyone with a personal or family history of medullary thyroid carcinoma or MEN2, on the basis of rodent tumours that have not been demonstrated in humans.
Loss of lean tissue alongside fat applies here as across the class, though it scales with total weight lost, so it is a smaller consideration than with the stronger drugs.
How it is dosed and administered
Liraglutide is licensed and its label was written from the trial data, which makes this section short and more reliable than anything reported second-hand.
It is a once-daily subcutaneous injection from a pre-filled pen, starting low and increasing weekly to the target dose. The weight management and diabetes products use different target doses under different licences.
Dose, escalation and stopping are decisions for the prescriber.
Liraglutide compared with semaglutide and tirzepatide
Against semaglutide
Semaglutide produces roughly twice the weight loss, needs one injection a week rather than seven, and has its own cardiovascular outcomes trial. On almost every axis it is the better drug.
Liraglutide's remaining advantages are availability, price now that generics exist, its adolescent licence, and the longest safety record in the family.
Against tirzepatide
Tirzepatide acts on two receptors and reached about 20% weight loss, against liraglutide's 8%. The gap is large. Tirzepatide has no completed cardiovascular outcomes trial, which is the one place the older drug still holds an edge.
Against the newer experimental compounds
Retatrutide reported up to 28.3% in phase 3 and is not approved anywhere. Liraglutide's contribution to that story is that it established the class was worth pursuing at all.
Frequently asked questions
Why would anyone take a daily injection over a weekly one?
Cost, availability, and the adolescent licence. Where the weekly drugs are unavailable or unaffordable, an 8% option that exists beats a 15% option that does not.
Is it as safe as the newer drugs?
It has the longest record of any drug in the family, over a decade of prescribing. On safety specifically, it is the best characterised.
Saxenda or Victoza?
The same molecule at different doses under different licences: Victoza for type 2 diabetes, Saxenda for weight management.
Does the weight come back if you stop?
Yes, as across the class. The drug reduces appetite while it is present and does not reset anything, so appetite regulation returns when it clears.
Key takeaways
- Liraglutide is a daily GLP-1 receptor agonist, licensed for type 2 diabetes since 2010 and for weight management since 2014.
- The SCALE trials reported around 8% mean body weight loss over a year, roughly half what semaglutide achieves.
- LEADER showed a reduction in major cardiovascular events. Liraglutide and semaglutide are the only two in this family with that evidence completed.
- It retains a role on cost, availability and its licence in adolescents aged 12 and over, and it has the longest safety record in the class.
- Persistent severe abdominal pain warrants urgent attention, and the label excludes a personal or family history of medullary thyroid carcinoma or MEN2.
References
- Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 2015. The SCALE trial.
- Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016. The LEADER trial.
- The compound page on this site: liraglutide.